In this episode of the “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by Travis Engelhaupt, digital experience director, and Naomi Lovell, project manager. Together, they discuss website trends and best practices.

Register now – Nov. 19, 2025: Regulatory compliance and recent policy changes at the federal and state levels relevant to hospital laboratory outreach programs.

Launch or refresh your lab newsletter with five key steps to engage, inform, and build stronger connections with your audience.

This "Phlebotomy webinar" focuses on the origins of difficult collections and the situations that result in them.

This week’s research roundup features a study on the epidemiology, natural history, and optimal management of neurohypophyseal germ cell tumors.

In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., will discuss recent information on the advantages and disadvantages of using butterfly needles for blood collection.

In January 2020, Mayo Clinic Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

At Mayo Clinic, we offer a comprehensive approach to testing that focuses on the best outcomes for the patient. Our testing method combines molecular and cytogenetic analysis (in addition to a standard morphological and histological assessment) to provide a clear picture of the diagnosis, prognosis, and treatment options. This approach maximizes the amount of information available, allowing for a tailored treatment plan.

Divyanshu Dubey, M.B.B.S. gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.

This week’s research roundup features a study on the impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain Amyloidosis.

Linda Baughn Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

Rondell Graham, M.B.B.S., an anatomic and molecular consultant at Mayo Clinic, co-led a molecular oncology tumor board session at CAP19, and subsequently spoke with CAP Today.

Elitza Theel, Ph.D., Director of the Infectious Diseases Serology Laboratory, Co-Director of the Vector-Borne Diseases Laboratory, and Associate Professor of Laboratory Medicine and Pathology, was recently interviewed by CAP Today about new Lyme disease testing.

Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff will be in Los Angeles, California, for the 109th United States and Canadian Academy of Pathology Meeting (USCAP). Visit us at booth #716 on March 2 - 4, 2020 to discuss how our testing can integrate with your practice.

Autoimmune encephalitis and myelitis is increasingly recognized as a cause of CNS disease in children and teens. Andrew McKeon, M.B., B.Ch., M.D, gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.